Tempus AI (NASDAQ:TEM) Trading Up 6.8% – Time to Buy?

Tempus AI, Inc. (NASDAQ:TEM)’s stock price was up 6.8% during mid-day trading on Monday . The stock traded as high as $91.45 and last traded at $89.44. Approximately 25,048,636 shares were traded during mid-day trading, an increase of 93% from the average daily volume of 12,947,475 shares. The stock had previously closed at $83.75.

Analysts Set New Price Targets

Several research analysts recently issued reports on TEM shares. William Blair lowered shares of Tempus AI from an “outperform” rating to a “market perform” rating in a research report on Wednesday, February 12th. Bank of America increased their price target on shares of Tempus AI from $52.00 to $54.00 and gave the stock a “neutral” rating in a research report on Friday, December 13th. Needham & Company LLC reaffirmed a “buy” rating and set a $56.00 price objective on shares of Tempus AI in a report on Tuesday, January 14th. TD Cowen reaffirmed a “buy” rating and set a $74.00 price objective (up previously from $58.00) on shares of Tempus AI in a report on Wednesday, February 5th. Finally, Piper Sandler reaffirmed a “neutral” rating and set a $70.00 price objective (up previously from $40.00) on shares of Tempus AI in a report on Tuesday, November 12th. Four investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat, Tempus AI has an average rating of “Moderate Buy” and a consensus price target of $58.55.

Tempus AI Price Performance

The company has a quick ratio of 2.55, a current ratio of 2.69 and a debt-to-equity ratio of 8.17. The business’s fifty day moving average is $47.46 and its two-hundred day moving average is $50.72.

Insider Activity at Tempus AI

In other Tempus AI news, CEO Eric P. Lefkofsky sold 476,209 shares of the firm’s stock in a transaction that occurred on Wednesday, January 22nd. The shares were sold at an average price of $49.84, for a total value of $23,734,256.56. Following the transaction, the chief executive officer now directly owns 6,502,643 shares of the company’s stock, valued at approximately $324,091,727.12. This trade represents a 6.82 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Andrew Polovin sold 51,504 shares of the firm’s stock in a transaction that occurred on Wednesday, December 11th. The shares were sold at an average price of $42.39, for a total transaction of $2,183,254.56. Following the completion of the transaction, the executive vice president now directly owns 246,085 shares in the company, valued at approximately $10,431,543.15. The trade was a 17.31 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 2,401,779 shares of company stock valued at $115,707,361 over the last quarter.

Hedge Funds Weigh In On Tempus AI

A number of hedge funds and other institutional investors have recently bought and sold shares of TEM. Operose Advisors LLC bought a new position in Tempus AI in the fourth quarter valued at approximately $25,000. First Horizon Advisors Inc. bought a new position in Tempus AI in the third quarter valued at approximately $30,000. Farther Finance Advisors LLC bought a new position in Tempus AI in the fourth quarter valued at approximately $34,000. Prestige Wealth Management Group LLC boosted its stake in Tempus AI by 910.4% in the fourth quarter. Prestige Wealth Management Group LLC now owns 1,071 shares of the company’s stock valued at $36,000 after acquiring an additional 965 shares during the last quarter. Finally, NewEdge Advisors LLC bought a new position in Tempus AI in the fourth quarter valued at approximately $49,000. 24.22% of the stock is owned by institutional investors.

Tempus AI Company Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.